Back to Search Start Over

Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

Authors :
Porsbjerg, Celeste M.
Townend, John
Bergeron, Celine
Christoff, George C.
Katsoulotos, Gregory P.
Larenas-Linnemann, Desiree
Tran, Trung N.
Al-Lehebi, Riyad
Bosnic-Anticevich, Sinthia Z.
Busby, John
Hew, Mark
Kostikas, Konstantinos
Papadopoulos, Nikolaos G.
Pfeffer, Paul E.
Popov, Todor A.
Rhee, Chin Kook
Sadatsafavi, Mohsen
Tsai, Ming-Ju
Ulrik, Charlotte Suppli
Al-Ahmad, Mona
Altraja, Alan
Beastall, Aaron
Bulathsinhala, Lakmini
Carter, Victoria
Cosio, Borja G.
Fletton, Kirsty
Hansen, Susanne
Heaney, Liam G.
Hubbard, Richard B.
Kuna, Piotr
Murray, Ruth B.
Nagano, Tatsuya
Pini, Laura
Rosales, Diana Jimena Cano
Schleich, Florence
Wechsler, Michael E.
Amaral, Rita
Bourdin, Arnaud
Brusselle, Guy G.
Chen, Wenjia
Chung, Li Ping
Denton, Eve
Fonseca, Joao A.
Hoyte, Flavia
Jackson, David J.
Katial, Rohit
Kirenga, Bruce J.
Koh, Mariko Siyue
Lawkiedraj, Agnieszka
Lehtimaki, Lauri
Liew, Mei Fong
Mahboub, Bassam
Martin, Neil
Menzies-Gow, Andrew N.
Pang, Pee Hwee
Papaioannou, Andriana I.
Patel, Pujan H.
Perez-De-Llano, Luis
Peters, Matthew J.
Ricciardi, Luisa
Rodriguez-Caceres, Bellanid
Solarte, Ivan
Tay, Tunn Ren
Torres-Duque, Carlos A.
Wang, Eileen
Zappa, Martina
Abisheganaden, John
Assing, Karin Dahl
Costello, Richard W.
Gibson, Peter G.
Heffler, Enrico
Maspero, Jorge
Nicola, Stefania
Steve, Diahn-Warng Perng
Puggioni, Francesca
Salvi, Sundeep
Sheu, Chau-Chyun
Sirena, Concetta
Taille, Camille
Tan, Tze Lee
Bjermer, Leif
Canonica, Giorgio Walter
Iwanaga, Takashi
Jimenez-Maldonado, Libardo
Taube, Christian
Brussino, Luisa
Price, David B.
Porsbjerg, Celeste M.
Townend, John
Bergeron, Celine
Christoff, George C.
Katsoulotos, Gregory P.
Larenas-Linnemann, Desiree
Tran, Trung N.
Al-Lehebi, Riyad
Bosnic-Anticevich, Sinthia Z.
Busby, John
Hew, Mark
Kostikas, Konstantinos
Papadopoulos, Nikolaos G.
Pfeffer, Paul E.
Popov, Todor A.
Rhee, Chin Kook
Sadatsafavi, Mohsen
Tsai, Ming-Ju
Ulrik, Charlotte Suppli
Al-Ahmad, Mona
Altraja, Alan
Beastall, Aaron
Bulathsinhala, Lakmini
Carter, Victoria
Cosio, Borja G.
Fletton, Kirsty
Hansen, Susanne
Heaney, Liam G.
Hubbard, Richard B.
Kuna, Piotr
Murray, Ruth B.
Nagano, Tatsuya
Pini, Laura
Rosales, Diana Jimena Cano
Schleich, Florence
Wechsler, Michael E.
Amaral, Rita
Bourdin, Arnaud
Brusselle, Guy G.
Chen, Wenjia
Chung, Li Ping
Denton, Eve
Fonseca, Joao A.
Hoyte, Flavia
Jackson, David J.
Katial, Rohit
Kirenga, Bruce J.
Koh, Mariko Siyue
Lawkiedraj, Agnieszka
Lehtimaki, Lauri
Liew, Mei Fong
Mahboub, Bassam
Martin, Neil
Menzies-Gow, Andrew N.
Pang, Pee Hwee
Papaioannou, Andriana I.
Patel, Pujan H.
Perez-De-Llano, Luis
Peters, Matthew J.
Ricciardi, Luisa
Rodriguez-Caceres, Bellanid
Solarte, Ivan
Tay, Tunn Ren
Torres-Duque, Carlos A.
Wang, Eileen
Zappa, Martina
Abisheganaden, John
Assing, Karin Dahl
Costello, Richard W.
Gibson, Peter G.
Heffler, Enrico
Maspero, Jorge
Nicola, Stefania
Steve, Diahn-Warng Perng
Puggioni, Francesca
Salvi, Sundeep
Sheu, Chau-Chyun
Sirena, Concetta
Taille, Camille
Tan, Tze Lee
Bjermer, Leif
Canonica, Giorgio Walter
Iwanaga, Takashi
Jimenez-Maldonado, Libardo
Taube, Christian
Brussino, Luisa
Price, David B.
Publication Year :
2024

Abstract

Background: To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials. Aim: To elucidate the associations of pre-biologic individual biomarker levels or their combinations with pre-to-post biologic changes in asthma outcomes in real-life. Methods: This was a registry-based, cohort study using data from 23 countries, which shared data with the International Severe Asthma Registry (May 2017-February 2023). The investigated biomarkers (highest pre-biologic levels) were immunoglobulin E (IgE), blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO). Pre- to approximately 12-month post-biologic change for each of three asthma outcome domains (i.e. exacerbation rate, symptom control and lung function), and the association of this change with pre-biologic biomarkers was investigated for individual and combined biomarkers. Results: Overall, 3751 patients initiated biologics and were included in the analysis. No association was found between pre-biologic BEC and pre-to-post biologic change in exacerbation rate for any biologic class. However, higher pre-biologic BEC and FeNO were both associated with greater post-biologic improvement in FEV1 for both anti-IgE and anti-IL5/5R, with a trend for antiI-IL4R alpha. Mean FEV1 improved by 27-178 mL post-anti-IgE as pre-biologic BEC increased (250 to 1000 cells/mu L), and by 43-216 mL and 129-250 mL post-anti-IL5/5R and - anti- IL4R alpha, respectively along the same BEC gradient. Corresponding improvements along a FeNO gradient (25-100 ppb) were 41-274 mL, 69-207 mL and 148-224 mL for anti-IgE, anti-IL5/5R, and anti-IL4R alpha, respectively. Higher baseline BEC was also associated with lower probability of uncontrolled asthma (OR 0.392; p=0.001) post-biologic for anti-IL5/5R. Pre-biologic IgE was a poor predictor of subsequent pre-to-post-biologic change for

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1457590832
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.3389.fimmu.2024.1361891